| Literature DB >> 35056820 |
Zildene de Sousa Silveira1,2, Nair Silva Macêdo1,2, Suieny Rodrigues Bezerra1, Abolghasem Siyadatpanah3, Henrique Douglas Melo Coutinho4, Zahra Seifi5, Bonglee Kim6,7, Francisco Assis Bezerra da Cunha1, Valdir de Queiroz Balbino2.
Abstract
Amburana cearensis (Allemão) ACSm. belongs to the Fabaceae family and occurs in the Brazilian semiarid, Argentina, Paraguay, Bolivia, and Peru. Numerous studies that portray its ethnobotany, use in popular medicine, chemical composition, and biological activities exist in the literature. This review aimed to provide an overview of the chemical composition, ethnopharmacology, and biological activities associated with A. cearensis and its isolated constituents. Information was collected from internet searches in the Scopus, Medline, PubMed, Google Scholar, and ScienceDirect databases were performed covering publications from 1997-2020. An ethnopharmacological literature analysis revealed that A. cearensis is used to treat a wide range of respiratory disorders in addition to intestinal, circulatory, and inflammatory problems. Coumarins, flavonoids, phenolic glycosides, phenolic acids, phenylpropanoid derivatives, and triterpenoids, among others, have been reported as active compounds, with High-Performance Liquid Chromatography (HPLC) being the main analytical technique used. The A. cearensis extracts and compounds presented several biological activities, including antimicrobial, antinociceptive, anti-inflammatory, antioxidant, neuroprotective, and myorelaxant activities, among others. This review provides a useful bibliography for future investigations and A. cearensis applications; however, future studies should focus on its toxic effects and the mechanisms of action of its extracts and isolated constituents to guide clinical applications.Entities:
Keywords: Amburana cearensis; coumarins; ethnopharmacology; pharmacology; phytochemistry
Mesh:
Substances:
Year: 2022 PMID: 35056820 PMCID: PMC8781860 DOI: 10.3390/molecules27020505
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Chemical compounds identified in A. Cearensis by differents analytical techniques.
| Part Used | Solvents | Analytical | Compounds | Citations |
|---|---|---|---|---|
| Stem bark | Petrol, CH2Cl2, and ethyl acetate | VLC | Coumarin and amburoside A and B | [ |
| Hexane, chloroform, ethyl acetate, acetone, and methanol | GC/EIMS | Dihydrocumarin; scopoletin; | [ | |
| Ethanol | HPLC | Coumarin; | [ | |
| Hexane | HPLC | Amburosides (A and C-H); 6-coumaryl protocatechuate; 6-hydroxycoumarin, | [ | |
| Chloroform | GC/MS | 4-methoxy-3-methylphenol; tricyclene; α-pinene; β-pinene and 4-hydroxybenzoic acid | [ | |
| Ethanol | HPLC | Protocatechuic acid; | [ | |
| Seeds | Hexane, dichloromethane, ethyl acetate, and ethanol | GC/MS | Coumarin, gallic acid, and | [ |
| Ethanol, hexane, dichloromethane and ethyl acetate | HPLC | Coumarin; 3-methyl-coumarin; methyl hexadecanoate; methyl 9- | [ | |
| Ethanol | HPLC | Gallic acid; catechin; rutin; ellagic acid; naringin; myricetin and morin | [ | |
| Leaves | Ethanol | HPLC/DAD | Protocatechuic acid; | [ |
| Resin | Methanol | UPLC-DAD-QTOF-MS/MS) | Dilmin; lulin; erycibenin D; 7,8,3′-trihydroxy-4′-methoxyisoflavone; 7,8,3′-trihydroxy-6,4′-dimethoxyisoflavone; 3′-dihydroxy-8,4′-dimethoxyisoflavone; calycosin; odoratin; butein; cladrastrin; pratensein; 3′,4′-dimethoxy-1′-(7-methoxy-4-oxo-4H-chromen-3-yl)benzo-2′,5′-quinone; isoliquiritigenin and homobutein | [ |
| Young cultivated plants | Ethanol | HPLC | [ | |
| Ethanol | HPLC | Vanillic acid and coumarin | [ |
VLC: Vacuum liquid chromatography; GC/EIMS: gas chromatography with electron impact mass spectrometry; HPLC: high-performance liquid chromatography; GC/MS: gas chromatography coupled to mass spectrometry; HPLC/DAD: high-performance liquid chromatography equipped with a diode array detector; UPLC-DAD-QTOF-MS/MS): ultra-performance liquid chromatography coupled with diode array and quadrupole time-of-flight mass spectrometry.
Figure 1Chemical structures of the main compounds from A. cearensis.
Biological activities of Amburana cearensis.
| Activity Tested | Extract/Part | Model Used | Concentrations/Dosage | Citations |
|---|---|---|---|---|
| Antibacterial | Ethanol/stem bark | MBC—125; 145.8; 333.33; 31.25; 83.33; 145.8; 166.7; 166.7; 187.5; 187.5; 125; 41.67; 62.5; 281.3; 104.2; 250; 83.33; 125; 31.25; 125; 62.5 µL/mL, respectively | [ | |
| Ethanol/leaves | MIC—512 μg/mL | [ | ||
| Hydroalcoholic | MBC—9.375 μg/mL. | [ | ||
| Ethanol | MBC—390.6; 1.302; and 911.4 μg/mL, respectively | [ | ||
| Ethanol/stem bark | MBC—12.500 μg/mL | [ | ||
| Chloroform/stem bark | MIC—6900 µg/mL | [ | ||
| Ethanol/seeds | MIC: 1000; 250; 250; 500; and 250 μg/mL, respectively | [ | ||
| Crude and fractions (ammonium sulfate concentration: 0–30%, 30–60% and 60–90%/seeds | MIC ≥ 1024 μg/mL | [ | ||
| Antifungal | Proteic fractions/seeds | Filamentous fungi: 160 μg/mL; | [ | |
| Antinociceptive and antiedematogenic | Hydroalcoholic/stem bark | Swiss mice and Wistar rats | 100 and 200 mg/kg | [ |
| Hydroalcoholic/stem bark | Swiss mice and Wistar rats | 100 and 200 mg/kg, respectively | [ | |
| Hydroalcoholic/stem bark | Mice BALB/c | 200 mg/kg and 400 mg/kg | [ | |
| Ethanol/stem bark | Swiss mice and Wistar rats | 100; 200 and 400 mg/kg | [ | |
| Aqueous/seeds |
| 10 and 20% | [ | |
| Anti-inflammatory | Hydroalcoholic/stem bark | Wistar rats | 200 and 400 mg/kg | [ |
| Myorelaxant | Hydroalcoholic/stem bark | Guinea-pig isolated trachea | EC50: 3.64 ± 0.4 mg/mL | [ |
| Hydroalcoholic/stem bark | Guinea-pig isolated trachea | IC50 3.16 ± 0.55 mg/mL | [ | |
| Antioxidant | Ethanol/leaves and bark. Methanol and ethyl acetate fractions/leaves | DPPH | 0.1 and 1 mg/mL | [ |
| Ethanol/seeds | DPPH | IC50 17.95 μg/mL | [ | |
| Neuroprotective | Ethanolic, hexane, dichloromethane, and ethyl acetate/seeds | Neural PC12 cells | 0.1–1000 µg/mL | [ |
| Ethanol and dichloromethane/seeds | Cerebellar cells of wistar rats | 0.1 µg/mL | [ | |
| Dry extract and phenol fraction | Microglial cells | 5–200 mg/mL | [ | |
| Antiproliferative | Hydroalcoholic/stem powder | HaCaT; MDA-MB-231 and MCF7; 4T1 | 31.25; 62.5; 125; 250; 500; and 1000 μg/mL | [ |
| Hexane/seeds | Cerebellar cells of Wistar rats | 1000 µg/mL | [ | |
| Allelopathic | Aqueous and metanol/seeds |
| 5, 10, and 15 g; 1; 5; 10; and 15 g, respectively | [ |
| Aqueous and methanol/seeds | 15 g | [ | ||
| Aqueous extract/leaves |
| 50 and 100 g/L | [ | |
| Hydroalcoholic extract/seeds | 1; 0.5; and 0.25% | [ | ||
| Hydroalcoholic/leaves | 1; 0.5; and 0.25% | [ | ||
| Hexane and dichloromethane fracionas/seeds | 1 and 0.5% | [ | ||
| Survival of preantral follicles | Ethanol/leaves | Ovarian cortical tissues goats | 0.2 mg/ml | [ |
| Ethanol/leaves | Ovarian cortical tissues ovine ( | 0.1 mg/mL | [ | |
| Ethanol/leaves | Ovarian cortical tissues ovine | 0.2 mg/mL | [ | |
| Larvicidal | Aqueous/seeds |
| LC50 8.10 ± 0. 27 mg/mL after 24 h of exposure | [ |
| Repellency | Powder/leaves and bark |
| 2 g | [ |
| Acaricidal | Hexane fraction/leaves | 25 mg/mL | [ | |
| Mutagenic | Aqueous/seeds | Meristematic cells of | 0.1 mg/mL and 0.5 mg/mL | [ |
| Photoprotective | Ethanol/leaves | - | SPF = 17.60 | [ |
HaCaT: human keratinocytes; MDA-MB-231 and MCF7: human breast adenocarcinoma; 4T1: Mouse tumor mammary gland; MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration; LC50: median lethal concentration; DPPH: 2,2-Diphenyl-1-picrylhydrazyl radical; SPF: protection factor.
Biological activities of compounds isolated from A. cearensis.
| Phytochemicals | Activity Tested | Model Used | Concentraction | Citations |
|---|---|---|---|---|
| Coumarin (1) | Antinociceptive and antiedematogenic | Swiss mice and Wistar rats | 5–20 mg/kg and 10 mg/kg | [ |
| Coumarin (1) | Anti-inflammatory, antinociceptive | Swiss mice and Wistar rats | 5; 10; and 20 mg/kg | [ |
| Coumarin (1) | Anti-inflammatory | Wistar rats | 20 and 40 mg/kg | [ |
| Coumarin (1) | Anti-inflammatory and antiedematogenic | BALB/c mice | 10 and 20 mg/mL | [ |
| Coumarin (1) | Myorelaxant | Guinea pig trachea | EC50 0.08 ± 0.01 mg/mL | [ |
| Coumarin (1) | Myorelaxant | Guinea pig trachea | IC50 0.045 ± 0.013; 0.084 ± 0.016 and 0.087 ± 0.006 mg/mL (carbachol, histamine and KCl) | [ |
| Coumarin (1) | Antileishmanial | 25; 50; 100; 250; and 500 mg/mL | [ | |
| Amburoside A (2) | Antiedematogenic and anti-inflammatory | Swiss mice and Wistar rats | 25 and 50 mg/kg | [ |
| Amburoside A (2) | Neuroprotective | Rat microglial cell cultures | 5-200 mg/mL | [ |
| Amburoside A (2) | Hepatoprotective | CCl4-induced hepatotoxicity in Wistar rats | 25 and 50 mg/kg | [ |
| Isokaempferide (3) | Cytotoxic | CEM; HL-60; HCT-8; MCF-7 and B-16 | IC50: 2.6 μg/mL (CEM); 3.0 μg/mL (HL-60); 5.4 μg/mL (HCT-8); 5.5 μg/mL (MCF-7); and 3.6 μg/mL (B-16) | [ |
| Amburanins A and B (4 and 5) | Anti-inflammatory | Human neutrophils | 25; 50 and 100 μg/mL | [ |
| Vanillic acid (6) | Antinociceptive, antiedematogenic and anti-inflammatory | Swiss mice and Wistar rats | 25 and 50 mg/kg | [ |
| Afrormosin (7) | Anti-inflammatory | Human neutrophils stimulated by | IC50 66.70 μM (fMLP) and 0.374 μM (PMA); | [ |
| Afrormosin (7) | Antioxidant | Human neutrophils (chemiluminescent | CL50: Lucigenin (>100 μg/mL) and luminol (19.09 μg/mL) | [ |
| Protecatechuic acid (8) | Cytotoxic | CEM; HL-60; HCT-8; MCF-7; and B-16 | IC50: >25.0 (CEM); 20.7 (HL-60); >25.0 (HCT-8); >25.0 (MCF-7); >25.0 μg/mL (B-16) | [ |
| Kaempferol (9) | Cytotoxic | CEM; HL-60; HCT-8; MCF-7; and B-16 | IC50 13.4 μg/mL (CEM); 22.7 μg/mL (HL-60); 15.2 | [ |
| 2-methoxy-4-methylphenol | Antibacterial | MIC—215; 215; 431; 431; 215; 215; and 215 µg/mL, respectively | [ |
EC50: half maximal efective concentration; IC50: half maximal inhibitory concentration; CL50: median lethal concentration; B-16 (murine skin cancer); HCT-8 (human colon cancer); MCF-7 (human breast cancer); CEM and HL-60 (leukemia cancer); MPO: mieloperoxidase; fMLP: formyl-methionyl-leucyl-phenylalanine; PMA: phorbol-12-myristate-13-acetate; TNF-α: tumor necrosis factor alpha.